Displaying 1261 - 1280 of 4528
1904004 Informal Interpretation
Tronox/Cristal USA; Analysis of Agreement Containing Consent Orders To Aid Public Comment
1904005 Informal Interpretation
Merger Retrospective Lessons from Mr. Rogers
FTC to Hold Workshop on Certificates of Public Advantage in Healthcare Markets
FTC Hearings on Competition and Consumer Protection in the 21st Century Continue with a Discussion of Merger Retrospectives
FTC Requires Divestitures by Tronox and Cristal, Suppliers of Widely Used White Pigment, Settling Litigation over Proposed Merger
FTC Approves Final Order Imposing Conditions on Merger of Fresenius Medical Care AG & KGaA and NxStage Medical, Inc.
Fresenius Medical Care and NxStage Medical, In the Matter of
The FTC required healthcare companies Fresenius Medical Care AG & KGaA and NxStage Medical, Inc. to divest all rights and assets related to NxStage’s bloodline tubing set business to B. Braun Medical, Inc. as part of a settlement resolving charges that Fresenius’s proposed $2 billion acquisition of NxStage likely would be anticompetitive. The FTC’s complaint alleges that the proposed merger would harm competition in the U.S. market for bloodline tubing sets that are compatible with hemodialysis machines used in clinics that treat chronic renal failure. Bloodline tubing sets are single-use plastic tube sets used during hemodialysis treatments. Fresenius and NxStage are two of only three significant suppliers of bloodline tubing sets used in open architecture hemodialysis machines in the United States. Fresenius and NxStage together control 82 percent of the market for bloodlines.The settlement requires Fresenius and NxStage to divest to B. Braun all assets and rights to research, develop, manufacture, market, and sell NxStage’s bloodline tubing sets.
Statement of the FTC’s Bureau of Competition Regarding Announcement that Republic National Distributing Company and Breakthru Beverage Group have Terminated Their Acquisition Agreement
Displaying 1261 - 1280 of 4528